cisplatin + etoposide + cetuximab

This drug is a **three-drug combination chemotherapy regimen** composed of cisplatin, etoposide, and cetuximab. - **Cisplatin** is a platinum-based cytotoxic agent that forms DNA crosslinks, leading to apoptosis and inhibition of cancer cell proliferation. - **Etoposide** is a topoisomerase II inhibitor that causes DNA strand breaks during replication, preventing cell division in rapidly growing tumors. - **Cetuximab** is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (**EGFR**), inhibiting downstream signaling involved in cell growth and survival. This combination leverages **multiple mechanisms of action** to increase antitumor activity and is under investigation or used off-label in several cancer types, including lung and gastrointestinal cancers. The rationale is to harness the cytotoxic activity of cisplatin and etoposide with the targeted inhibition of EGFR signaling by cetuximab, which may overcome resistance and enhance efficacy in EGFR-expressing tumors[2][4]. Clinical trials and preclinical studies indicate that cetuximab can inhibit cisplatin-induced EGFR activation, potentially improving treatment response in certain cancers[2][4]. The overall toxicity profile reflects contributions from each agent, including hematologic toxicities, nephrotoxicity (from cisplatin), immunologic reactions (from cetuximab), and gastrointestinal toxicity[5][6][8].

Other names

cisplatin plus etoposide and cetuximab